{"id":32833,"date":"2025-07-30T08:47:02","date_gmt":"2025-07-30T08:47:02","guid":{"rendered":"https:\/\/ibima.eu\/estudio-fase-iii-abierto-aleatorizado-de-atezolizumab-y-tiragolumab-en-comparacion-con-durvalumab-en-pacientes-con-cancer-de-pulmon-no-microcitico-localmente-avanzado-en-estadio-iii-irresecable-que\/"},"modified":"2025-07-30T08:47:02","modified_gmt":"2025-07-30T08:47:02","slug":"estudio-fase-iii-abierto-aleatorizado-de-atezolizumab-y-tiragolumab-en-comparacion-con-durvalumab-en-pacientes-con-cancer-de-pulmon-no-microcitico-localmente-avanzado-en-estadio-iii-irresecable-que","status":"publish","type":"post","link":"https:\/\/ibima.eu\/es\/estudio-fase-iii-abierto-aleatorizado-de-atezolizumab-y-tiragolumab-en-comparacion-con-durvalumab-en-pacientes-con-cancer-de-pulmon-no-microcitico-localmente-avanzado-en-estadio-iii-irresecable-que\/","title":{"rendered":"Estudio fase III, abierto, aleatorizado de atezolizumab y tiragolumab en comparaci\u00f3n con durvalumab en pacientes con c\u00e1ncer de pulm\u00f3n no microc\u00edtico localmente avanzado en estadio III irresecable que no han presentado progresi\u00f3n despu\u00e9s de quimiorradioterapia con platino concomitante (skyscraper-03)"},"content":{"rendered":"

MANUEL COBO DOLS – ENSAYO CLINICO COMERCIAL – III – Roche Registration Limited<\/p>\n","protected":false},"excerpt":{"rendered":"

MANUEL COBO DOLS – ENSAYO CLINICO COMERCIAL – III – Roche Registration Limited<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[2263,2683],"tags":[],"class_list":["post-32833","post","type-post","status-publish","format-standard","hentry","category-ensayos-clinicos","category-ensayos-clinicos-b-22"],"acf":[],"yoast_head":"\nEstudio fase III, abierto, aleatorizado de atezolizumab y tiragolumab en comparaci\u00f3n con durvalumab en pacientes con c\u00e1ncer de pulm\u00f3n no microc\u00edtico localmente avanzado en estadio III irresecable que no han presentado progresi\u00f3n despu\u00e9s de quimiorradioterapia con platino concomitante (skyscraper-03) - Ibima<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ibima.eu\/es\/estudio-fase-iii-abierto-aleatorizado-de-atezolizumab-y-tiragolumab-en-comparacion-con-durvalumab-en-pacientes-con-cancer-de-pulmon-no-microcitico-localmente-avanzado-en-estadio-iii-irresecable-que\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Estudio fase III, abierto, aleatorizado de atezolizumab y tiragolumab en comparaci\u00f3n con durvalumab en pacientes con c\u00e1ncer de pulm\u00f3n no microc\u00edtico localmente avanzado en estadio III irresecable que no han presentado progresi\u00f3n despu\u00e9s de quimiorradioterapia con platino concomitante (skyscraper-03) - Ibima\" \/>\n<meta property=\"og:description\" content=\"MANUEL COBO DOLS – ENSAYO CLINICO COMERCIAL – III – Roche Registration Limited\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ibima.eu\/es\/estudio-fase-iii-abierto-aleatorizado-de-atezolizumab-y-tiragolumab-en-comparacion-con-durvalumab-en-pacientes-con-cancer-de-pulmon-no-microcitico-localmente-avanzado-en-estadio-iii-irresecable-que\/\" \/>\n<meta property=\"og:site_name\" content=\"Ibima\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-30T08:47:02+00:00\" \/>\n<meta name=\"author\" content=\"prodriguez\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"prodriguez\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/estudio-fase-iii-abierto-aleatorizado-de-atezolizumab-y-tiragolumab-en-comparacion-con-durvalumab-en-pacientes-con-cancer-de-pulmon-no-microcitico-localmente-avanzado-en-estadio-iii-irresecable-que\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ibima.eu\\\/estudio-fase-iii-abierto-aleatorizado-de-atezolizumab-y-tiragolumab-en-comparacion-con-durvalumab-en-pacientes-con-cancer-de-pulmon-no-microcitico-localmente-avanzado-en-estadio-iii-irresecable-que\\\/\"},\"author\":{\"name\":\"prodriguez\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/#\\\/schema\\\/person\\\/40b410344dd5ad2315bb651e3fbfa635\"},\"headline\":\"Estudio fase III, abierto, aleatorizado de atezolizumab y tiragolumab en comparaci\u00f3n con durvalumab en pacientes con c\u00e1ncer de pulm\u00f3n no microc\u00edtico localmente avanzado en estadio III irresecable que no han presentado progresi\u00f3n despu\u00e9s de quimiorradioterapia con platino concomitante (skyscraper-03)\",\"datePublished\":\"2025-07-30T08:47:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/ibima.eu\\\/estudio-fase-iii-abierto-aleatorizado-de-atezolizumab-y-tiragolumab-en-comparacion-con-durvalumab-en-pacientes-con-cancer-de-pulmon-no-microcitico-localmente-avanzado-en-estadio-iii-irresecable-que\\\/\"},\"wordCount\":58,\"commentCount\":0,\"articleSection\":[\"Ensayos Cl\u00ednicos\",\"Ensayos Cl\u00ednicos - B-22\"],\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/ibima.eu\\\/estudio-fase-iii-abierto-aleatorizado-de-atezolizumab-y-tiragolumab-en-comparacion-con-durvalumab-en-pacientes-con-cancer-de-pulmon-no-microcitico-localmente-avanzado-en-estadio-iii-irresecable-que\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/estudio-fase-iii-abierto-aleatorizado-de-atezolizumab-y-tiragolumab-en-comparacion-con-durvalumab-en-pacientes-con-cancer-de-pulmon-no-microcitico-localmente-avanzado-en-estadio-iii-irresecable-que\\\/\",\"url\":\"https:\\\/\\\/ibima.eu\\\/estudio-fase-iii-abierto-aleatorizado-de-atezolizumab-y-tiragolumab-en-comparacion-con-durvalumab-en-pacientes-con-cancer-de-pulmon-no-microcitico-localmente-avanzado-en-estadio-iii-irresecable-que\\\/\",\"name\":\"Estudio fase III, abierto, aleatorizado de atezolizumab y tiragolumab en comparaci\u00f3n con durvalumab en pacientes con c\u00e1ncer de pulm\u00f3n no microc\u00edtico localmente avanzado en estadio III irresecable que no han presentado progresi\u00f3n despu\u00e9s de quimiorradioterapia con platino concomitante (skyscraper-03) - Ibima\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/#website\"},\"datePublished\":\"2025-07-30T08:47:02+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/#\\\/schema\\\/person\\\/40b410344dd5ad2315bb651e3fbfa635\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/ibima.eu\\\/estudio-fase-iii-abierto-aleatorizado-de-atezolizumab-y-tiragolumab-en-comparacion-con-durvalumab-en-pacientes-con-cancer-de-pulmon-no-microcitico-localmente-avanzado-en-estadio-iii-irresecable-que\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/ibima.eu\\\/estudio-fase-iii-abierto-aleatorizado-de-atezolizumab-y-tiragolumab-en-comparacion-con-durvalumab-en-pacientes-con-cancer-de-pulmon-no-microcitico-localmente-avanzado-en-estadio-iii-irresecable-que\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/estudio-fase-iii-abierto-aleatorizado-de-atezolizumab-y-tiragolumab-en-comparacion-con-durvalumab-en-pacientes-con-cancer-de-pulmon-no-microcitico-localmente-avanzado-en-estadio-iii-irresecable-que\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\\\/\\\/ibima.eu\\\/es\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Estudio fase III, abierto, aleatorizado de atezolizumab y tiragolumab en comparaci\u00f3n con durvalumab en pacientes con c\u00e1ncer de pulm\u00f3n no microc\u00edtico localmente avanzado en estadio III irresecable que no han presentado progresi\u00f3n despu\u00e9s de quimiorradioterapia con platino concomitante (skyscraper-03)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/#website\",\"url\":\"https:\\\/\\\/ibima.eu\\\/es\\\/\",\"name\":\"Ibima\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/ibima.eu\\\/es\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/#\\\/schema\\\/person\\\/40b410344dd5ad2315bb651e3fbfa635\",\"name\":\"prodriguez\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/3e682b55f425f54644efd95284b890bfd6e129cc61dd791a9d4345ce1ed26791?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/3e682b55f425f54644efd95284b890bfd6e129cc61dd791a9d4345ce1ed26791?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/3e682b55f425f54644efd95284b890bfd6e129cc61dd791a9d4345ce1ed26791?s=96&d=mm&r=g\",\"caption\":\"prodriguez\"},\"sameAs\":[\"https:\\\/\\\/ibima.eu\"],\"url\":\"https:\\\/\\\/ibima.eu\\\/es\\\/author\\\/prodriguez\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Estudio fase III, abierto, aleatorizado de atezolizumab y tiragolumab en comparaci\u00f3n con durvalumab en pacientes con c\u00e1ncer de pulm\u00f3n no microc\u00edtico localmente avanzado en estadio III irresecable que no han presentado progresi\u00f3n despu\u00e9s de quimiorradioterapia con platino concomitante (skyscraper-03) - Ibima","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ibima.eu\/es\/estudio-fase-iii-abierto-aleatorizado-de-atezolizumab-y-tiragolumab-en-comparacion-con-durvalumab-en-pacientes-con-cancer-de-pulmon-no-microcitico-localmente-avanzado-en-estadio-iii-irresecable-que\/","og_locale":"es_ES","og_type":"article","og_title":"Estudio fase III, abierto, aleatorizado de atezolizumab y tiragolumab en comparaci\u00f3n con durvalumab en pacientes con c\u00e1ncer de pulm\u00f3n no microc\u00edtico localmente avanzado en estadio III irresecable que no han presentado progresi\u00f3n despu\u00e9s de quimiorradioterapia con platino concomitante (skyscraper-03) - Ibima","og_description":"MANUEL COBO DOLS – ENSAYO CLINICO COMERCIAL – III – Roche Registration Limited","og_url":"https:\/\/ibima.eu\/es\/estudio-fase-iii-abierto-aleatorizado-de-atezolizumab-y-tiragolumab-en-comparacion-con-durvalumab-en-pacientes-con-cancer-de-pulmon-no-microcitico-localmente-avanzado-en-estadio-iii-irresecable-que\/","og_site_name":"Ibima","article_published_time":"2025-07-30T08:47:02+00:00","author":"prodriguez","twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"prodriguez"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ibima.eu\/estudio-fase-iii-abierto-aleatorizado-de-atezolizumab-y-tiragolumab-en-comparacion-con-durvalumab-en-pacientes-con-cancer-de-pulmon-no-microcitico-localmente-avanzado-en-estadio-iii-irresecable-que\/#article","isPartOf":{"@id":"https:\/\/ibima.eu\/estudio-fase-iii-abierto-aleatorizado-de-atezolizumab-y-tiragolumab-en-comparacion-con-durvalumab-en-pacientes-con-cancer-de-pulmon-no-microcitico-localmente-avanzado-en-estadio-iii-irresecable-que\/"},"author":{"name":"prodriguez","@id":"https:\/\/ibima.eu\/es\/#\/schema\/person\/40b410344dd5ad2315bb651e3fbfa635"},"headline":"Estudio fase III, abierto, aleatorizado de atezolizumab y tiragolumab en comparaci\u00f3n con durvalumab en pacientes con c\u00e1ncer de pulm\u00f3n no microc\u00edtico localmente avanzado en estadio III irresecable que no han presentado progresi\u00f3n despu\u00e9s de quimiorradioterapia con platino concomitante (skyscraper-03)","datePublished":"2025-07-30T08:47:02+00:00","mainEntityOfPage":{"@id":"https:\/\/ibima.eu\/estudio-fase-iii-abierto-aleatorizado-de-atezolizumab-y-tiragolumab-en-comparacion-con-durvalumab-en-pacientes-con-cancer-de-pulmon-no-microcitico-localmente-avanzado-en-estadio-iii-irresecable-que\/"},"wordCount":58,"commentCount":0,"articleSection":["Ensayos Cl\u00ednicos","Ensayos Cl\u00ednicos - B-22"],"inLanguage":"es","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ibima.eu\/estudio-fase-iii-abierto-aleatorizado-de-atezolizumab-y-tiragolumab-en-comparacion-con-durvalumab-en-pacientes-con-cancer-de-pulmon-no-microcitico-localmente-avanzado-en-estadio-iii-irresecable-que\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ibima.eu\/estudio-fase-iii-abierto-aleatorizado-de-atezolizumab-y-tiragolumab-en-comparacion-con-durvalumab-en-pacientes-con-cancer-de-pulmon-no-microcitico-localmente-avanzado-en-estadio-iii-irresecable-que\/","url":"https:\/\/ibima.eu\/estudio-fase-iii-abierto-aleatorizado-de-atezolizumab-y-tiragolumab-en-comparacion-con-durvalumab-en-pacientes-con-cancer-de-pulmon-no-microcitico-localmente-avanzado-en-estadio-iii-irresecable-que\/","name":"Estudio fase III, abierto, aleatorizado de atezolizumab y tiragolumab en comparaci\u00f3n con durvalumab en pacientes con c\u00e1ncer de pulm\u00f3n no microc\u00edtico localmente avanzado en estadio III irresecable que no han presentado progresi\u00f3n despu\u00e9s de quimiorradioterapia con platino concomitante (skyscraper-03) - Ibima","isPartOf":{"@id":"https:\/\/ibima.eu\/es\/#website"},"datePublished":"2025-07-30T08:47:02+00:00","author":{"@id":"https:\/\/ibima.eu\/es\/#\/schema\/person\/40b410344dd5ad2315bb651e3fbfa635"},"breadcrumb":{"@id":"https:\/\/ibima.eu\/estudio-fase-iii-abierto-aleatorizado-de-atezolizumab-y-tiragolumab-en-comparacion-con-durvalumab-en-pacientes-con-cancer-de-pulmon-no-microcitico-localmente-avanzado-en-estadio-iii-irresecable-que\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ibima.eu\/estudio-fase-iii-abierto-aleatorizado-de-atezolizumab-y-tiragolumab-en-comparacion-con-durvalumab-en-pacientes-con-cancer-de-pulmon-no-microcitico-localmente-avanzado-en-estadio-iii-irresecable-que\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/ibima.eu\/estudio-fase-iii-abierto-aleatorizado-de-atezolizumab-y-tiragolumab-en-comparacion-con-durvalumab-en-pacientes-con-cancer-de-pulmon-no-microcitico-localmente-avanzado-en-estadio-iii-irresecable-que\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/ibima.eu\/es\/"},{"@type":"ListItem","position":2,"name":"Estudio fase III, abierto, aleatorizado de atezolizumab y tiragolumab en comparaci\u00f3n con durvalumab en pacientes con c\u00e1ncer de pulm\u00f3n no microc\u00edtico localmente avanzado en estadio III irresecable que no han presentado progresi\u00f3n despu\u00e9s de quimiorradioterapia con platino concomitante (skyscraper-03)"}]},{"@type":"WebSite","@id":"https:\/\/ibima.eu\/es\/#website","url":"https:\/\/ibima.eu\/es\/","name":"Ibima","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ibima.eu\/es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Person","@id":"https:\/\/ibima.eu\/es\/#\/schema\/person\/40b410344dd5ad2315bb651e3fbfa635","name":"prodriguez","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/secure.gravatar.com\/avatar\/3e682b55f425f54644efd95284b890bfd6e129cc61dd791a9d4345ce1ed26791?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/3e682b55f425f54644efd95284b890bfd6e129cc61dd791a9d4345ce1ed26791?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/3e682b55f425f54644efd95284b890bfd6e129cc61dd791a9d4345ce1ed26791?s=96&d=mm&r=g","caption":"prodriguez"},"sameAs":["https:\/\/ibima.eu"],"url":"https:\/\/ibima.eu\/es\/author\/prodriguez\/"}]}},"_links":{"self":[{"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/posts\/32833","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/comments?post=32833"}],"version-history":[{"count":3,"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/posts\/32833\/revisions"}],"predecessor-version":[{"id":55925,"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/posts\/32833\/revisions\/55925"}],"wp:attachment":[{"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/media?parent=32833"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/categories?post=32833"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/tags?post=32833"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}